Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …

Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
been shown to extend progression-free survival versus placebo when given to patients with …

Endometrioid ovarian carcinoma (EnOC) demonstrates substantial clinical and molecular
heterogeneity. Here, we report whole exome sequencing of 112 EnOC cases following …

Purpose: The abundance and effects of structural variation at BRCA1/2 in tumors are not well
understood. In particular, the impact of these events on homologous recombination repair …

Objective Investigate the clinical landscape of ovarian carcinoma (OC) over time. Design
Register‐based prospectively collected data. Setting South East Scotland. Sample A total of …

Objective To determine the rates of germline BRCA 1 and BRCA 2 mutations in Scottish
patients with ovarian cancer, before and after a change in testing policy. Design Retrospective …

Objectives The role of endocrine therapy (ET) in high grade serous ovarian carcinoma (HGSOC)
is poorly defined due to the lack of phase III data and significant heterogeneity of …

Background Disease relapse is the primary cause of death from ovarian carcinoma. Isolated
lymph node relapse is a rare pattern of ovarian carcinoma recurrence, with a reported …

Simple Summary Mucinous ovarian carcinoma (MOC) is a unique type of ovarian cancer.
While many MOC patients have excellent survival, patients who experience recurrence have …

Background Numerous studies have investigated the association between hormone receptor
expression and clinical outcome in ovarian carcinoma (OC); however, these have largely …